This weakness in the recommendations provided by guidelines is reflected in the wide range of rates of ophthalmoscopy in candidemic patients (53% to 75%) reported in the medical literature [22, 23]. In the same sense, although all patients included in the CANDIPOP study were prospectively followed by infectious disease specialists, we found that in “real life”, ophthalmoscopy was performed in less than 50% of the study population. In our fully publicly funded health care system, this low percentage cannot be attributed to cost- or reimbursement-related factors.